BRIEF—New chief executive at German liver disease startup

Germany’s HepaRegeniX has appointed Michael Lutz as chief executive and managing director, replacing Wolfgang Albrecht, who will become chief operating officer.

The 2017-founded pre-clinical developer is working on candidates based on a proprietary molecular target, Mitogen-Activated Protein (MAP) Kinase 4.

Dr Lutz was previously CEO of LifeCodexx, a company he led from its inception in 2010 through to its acquisition by Eurofins Scientific in 2017.

HepaRegeniX appointed Birgit Jung as chief scientific officer in January 2019.